Rs 409 crore Sai Parenteral’s IPO issue opens today. Check price band, GMP and to subscribe or not

The initial public offer (IPO) of Sai Parenteral’s will open for bidding on Tuesday and will close on Friday March 27. The company plans to raise Rs 409 crore through the issue which is a combination of an offer for sale (OFS) and issuance of fresh equity. Ahead of the opening, the grey market premium (GMP) indicated a muted listing.

Sai Parenteral’s IPO price band

The company has set the price band at Rs 372– 392 per share and retail investors can make applications for a minimum of 1 lot which comprises 38 equity shares amounting to Rs 14,896.

The IPO's fresh issue aggregates up to Rs 285 crores while the OFS aggregates up to Rs 123.79 crores which includes anchor investor portion of 31,28,485 equity shares.

The company raised Rs 122.63 crore on Monday through five anchor investors.

Live Events

It has reserved 50% of the issue for qualified institutional buyers (QIBs), up to 35% for retail investors and 15% for non-institutional investors (NIIs).

Sai Parenteral’s IPO GMP

Shares of Sai Parenteral’s were not commanding any grey market premium (GMP) ahead of the opening of the issue. This implies a flat listing. The GMP is only an indicative price and could change as the issue progresses.

Sai Parenteral’s IPO net proceeds

The gross proceeds from the issue will be to the tune of Rs 285 crore. The company will utilise Rs 110.8 crore towards capacity expansion and upgradation of manufacturing facilities, Rs 18 crore for establishment of a new R&D Centre, Rs 14 crore towards repayment of borrowings, and Rs 33 crore for its working capital requirements.

About Sai Parenteral’s

Sai Parenteral’s (SPL) is a diversified pharmaceutical formulations company engaged in the business of branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products & services for the domestic and international markets. The company’s portfolio includes formulation products, covering both high-value and high-volume categories across therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, etc., with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments.

Sai Parenteral’s Financials

The company's revenue from operations in H1FY26 stood at Rs 303 crore while its profit after tax (PAT) stood at Rs 2 crore. For FY25, revenue stood at Rs 495 versus Rs 154 crore in FY24 and Rs 97 in FY23. The PAT stood at Rs 20 crore in FY25 versus Rs 8 crore in FY24 and Rs 4 crore in FY23.

Sai Parenteral’s IPO lead managers

The Book Running Lead Managers (BRLMs) is Arihant Capital Markets Ltd while the registrar to the issue is Bigshare Services Pvt Ltd.

Should you bid?

SBI Securities recommends that investors 'Subscribe' to the issue for the long term, valuing it at FY25 (proforma) P/E and EV/EBITDA multiples of 88.2X/46.3X respectively based on post-issue capital, which appears to be at a premium to its peers.

"SPL operates in the Branded Generic Formulations and CDMO businesses, with the product portfolio covering both high-value and high-volume categories across various therapeutic areas. SPL’s offerings span across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. Of these, the injectables dosage is a high margin segment for the company, and it plans to increase the share of injectables in the total revenue mix in the coming years. We believe Noumed’s 451 dossiers offer huge growth opportunity for SPL," this brokerage said.

(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)

(You can now subscribe to our ETMarkets WhatsApp channel)

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...moreless

(You can now subscribe to our ETMarkets WhatsApp channel)

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

...moreless

What affects the rupee more — crude oil prices, or FPI sale?

As countries trade gold for guns, can Indian defence stocks be quiet winners?

Looking for a job? This city has plenty, few takers

Soft drink’s Jio moment? RIL’s Campa tests Coke-Pepsi duopoly of 30 years.

Stock Radar: Glenmark Pharma stock retreats from March 2026 record highs; time to buy the dip?

4 stocks with consistent score improvement and upside potential of up to 22% in one year, according to analysts

1

2

3